drugset
drugset / Trial / NCT02744534

Targeted Fusion Biopsy of the Prostate

NCT02744534 ↗

Phase 2 Completed 21 enrolled Emory University National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than the standard 2-dimensional approach which uses only the TRUS to guide the biopsy.

Timeline

Start
2015-11
Primary completion
2018-03-31
Completion
2018-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluciclovine Diagnostic / imaging agent — Intravenous

Indications

prostate cancer